Parallax Volatility Advisers
CBAY

Parallax Volatility Advisers’s Cymabay Therapeutics CBAY Stock Holding History

Parallax Volatility Advisers’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,700
Closed -$234K – 2589
2023
Q3 		$234K Buy
+15,700
New +$208K ﹤0.01% 1780

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parallax Volatility Advisers's CBAY Position: Q4 2018 in Review

Parallax Volatility Advisers sold out of Cymabay Therapeutics (CBAY) in Q4 2018, closing a stake of 56 shares — an estimated $1K sold.

Parallax Volatility Advisers first reported a position in CBAY in Q2 2015 and held it in 12 quarters. The position peaked at $63K in Q2 2015. 131 funds tracked by Wall St. Rank hold CBAY as of Q4 2018.

  • Parallax Volatility Advisers reported no remaining Cymabay Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 56 Cymabay Therapeutics shares in Q4 2018, an estimated $1K.
  • Parallax Volatility Advisers first reported a position in Cymabay Therapeutics in Q2 2015 and held it in 12 quarters.
  • Parallax Volatility Advisers's Cymabay Therapeutics position peaked at $63K in Q2 2015.
  • 131 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2018.

Based on Parallax Volatility Advisers's 13F filing for Q4 2018, filed 14 Feb 2019.